Skip to main content

Table 1 Baseline clinical and demographic characteristics of the trial sample

From: Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial

 Entire cohort (n = 39)
Male gendera23 (59.0)
Age (years)b54.00 ± 8.7
Body mass index (kg/m2)b28.67 ± 4.5
Genotypea
1B
No cirrhosis26 (66.7)
Cirrhosis9 (23.1)
1A
No cirrhosis2 (5.1)
Cirrhosis2 (5.1)
FibroScan® scoresa
F1–221 (53.8)
F3–418 (46.2)
Previous protease inhibitor treatment
Telaprevir21 (53.8)
Boceprevir17 (43.6)
Simepravir1 (2.6)
Haemoglobin (g/dL)b14.83 ± 1.0
Platelets (103/μL)b180.18 ± 50.9
INRc1.00 (0.11)
ALT (IU/L)c56 (44)
AST (IU/L)c47 (37)
AP (IU/L)c74 (25)
GGT (IU/L)c61 (98)
Bilirubin (mg/dL)b0.66 ± 0.3
Albumin (g/dL)b4.27 ± 0.2
Creatinine (mg/dL)b0.76 ± 0.1
  1. an (%); b mean ± SD; cmedian (IQR)